00:53 , Jan 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Epilepsy Cell culture and rat studies identified a benzodiazepine-based triple-inhibitor of CACNA1G, CACNA1H and CACNA1I that could help treat epilepsy. Chemical synthesis and testing in HEK cells expressing the three calcium channels identified a pyridodiazepine...
07:00 , May 21, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Calcium channel voltage-dependent T type α 1H subunit (CACNA1H; Cav3.2) as a diagnostic marker of early-onset hypertension with primary aldosteronis

BiomarkersCACNA1HCalcium channelCav3.2Yale University...
07:00 , Jun 28, 2012 |  BC Innovations  |  Strategy

Pharma compounds at the crossroads

The National Center for Advancing Translational Sciences (NCATS) has disclosed details about the first library of therapeutics in its Discovering New Therapeutic Uses for Existing Molecules program (see "Repurposing pharma compounds"). The compounds provided...
07:00 , Jun 11, 2012 |  BioCentury  |  Emerging Company Profile

Xdynia: T type relief

Xdynia LLC spun out from Tau Therapeutics Inc. this year to develop oral small molecule inhibitors of a specific subset of voltage-dependent T type calcium channels that play a prominent role in pain signal transduction....
07:00 , Jul 30, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertension Postmeiotic segregation...
07:00 , Jun 11, 2009 |  BC Innovations  |  Cover Story

Eat, sleep, lose weight

Researchers at Merck & Co. Inc.may have found a way to tackle obesity by antagonizing T-type calcium channels, which are involved in sleep regulation. In rodents, the approach reduced diet-induced weight gain and increased lean...